Amplia Therapeutics Ltd. ( (AU:ATX) ) has shared an update.
Amplia Therapeutics has reported promising updated data from its ongoing ACCENT trial, which is evaluating the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown encouraging efficacy with 13 confirmed partial responses and good tolerability, suggesting that narmafotinib may enhance the effectiveness of chemotherapy. This data will be presented at the American Association of Cancer Research Annual Meeting, highlighting the drug’s potential impact on pancreatic cancer treatment and reinforcing Amplia’s position in the oncology sector.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer. FAK is a key target in cancer treatment and also plays a role in chronic diseases like idiopathic pulmonary fibrosis.
YTD Price Performance: 5.00%
Average Trading Volume: 13,559
Technical Sentiment Signal: Strong Buy
Current Market Cap: $17.12M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.